Related Experiment Videos
Treatment of prostatic carcinoma with cyproterone acetate
Abstract:
Sixteen patients with prostatic carcinoma were treated with 200 mg of Cyproterone acetate daily. No other kind of hormonal treatment was administered. Increasing skeletal metastases were observed in 6 patients, whereas significant reduction of metastases took place in 2 patients. Objective relief of stranguria was observed only in 3 patients. The amount of residual urine increased in 3 patients and was reduced in 5. In about one third of the patients, the prostate gland became smaller and softer. The acidic phosphatases decreased from pathological to normal values in 7 patients. There were no observed hepatic, renal or haemotological side-effects. However, serious cardio-vascular complications occurred in 6 patients, while arterial hypertension developed in 4. It is suggested that Cyproterone acetate cannot be recommended as the only kind of hormonal treatment of prostatic cancer.
Insights
Cyproterone acetate monotherapy showed limited efficacy for advanced prostatic carcinoma, with mixed results on metastases and urinary symptoms. Cardiovascular complications and hypertension were significant adverse events, questioning its sole use in prostate cancer treatment.
Area of Science:
- Oncology
- Endocrinology
Background:
- Prostatic carcinoma is a significant health concern.
- Hormonal therapy is a cornerstone in managing advanced prostate cancer.
Purpose of the Study:
- To evaluate the efficacy and safety of Cyproterone acetate as a sole hormonal treatment for prostatic carcinoma.
- To assess its impact on skeletal metastases, urinary symptoms, and prostate size.
Main Methods:
- Sixteen patients with prostatic carcinoma received 200 mg of Cyproterone acetate daily.
- No other hormonal treatments were administered concurrently.
- Outcomes including skeletal metastases, stranguria, residual urine, prostate size, and serum acid phosphatase levels were monitored.
Main Results:
- Mixed effects on skeletal metastases were observed (progression in 6, reduction in 2).
- Limited relief of stranguria (3 patients) and variable changes in residual urine volume.
- Prostate gland reduction and softening occurred in about one-third of patients.
- Acid phosphatase normalized in 7 patients.
- No hepatic, renal, or hematological side-effects were noted.
- Significant adverse events included cardiovascular complications (6 patients) and new-onset arterial hypertension (4 patients).
Conclusions:
- Cyproterone acetate monotherapy demonstrates insufficient efficacy for advanced prostatic carcinoma.
- The high incidence of serious cardiovascular complications and hypertension limits its therapeutic utility.
- It cannot be recommended as the exclusive hormonal treatment for prostate cancer.